All In Biotech

Drug Trial Radar · NCT03104400

A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD)

A Phase 3, Randomized, Double-Blind, Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Subjects With Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) - SELECT - PsA 1

Last checked: Nov 19, 2026Latest source record: Sep 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,705 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,705

Actual

Start

Apr 27, 2017

Primary completion

Sep 26, 2019

Study completion Sep 9, 2024

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Apr 7, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study includes two periods. The main objective of Period 1 is to compare the efficacy of upadacitinib 15 mg once daily (QD) and 30 mg QD versus placebo and versus adalimumab (Humira®) in participants with moderately to severely active psoriatic arthritis (PsA) who have had an inadequate response to non-biologic DMARDs (DMARD-IR). Period 1 is also designed to compare the efficacy of upadacitinib 15 mg and 30 mg QD versus placebo for the prevention of structural progression. The objective of Period 2 is to evaluate the long-term safety, tolerability and efficacy of upadacitinib 15 mg and 30 mg QD in participants who have completed Period 1.

Conditions

  • Psoriatic Arthritis

Interventions

  • AdalimumabDrug

    Administered by subcutaneous injection

  • UpadacitinibDrug

    Oral tablet

  • Placebo to UpadacitinibDrug

    Oral tablet

  • Placebo to AdalimumabDrug

    Administered by subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12Time frame: Baseline and Week 12

Locations

345 sites in 46 countries. Site status is shown where the registry gives one.

  • Rheum Assoc of North Alabama /ID# 163231

    Huntsville, Alabama

  • SunValley Arthritis Center, Lt /ID# 161221

    Peoria, Arizona

  • AZ Arthritis and Rheumotology Research, PLLC /ID# 159981

    Phoenix, Arizona

  • AZ Arthritis and Rheumotology Research, PLLC /ID# 160033

    Phoenix, Arizona

  • AZ Arthritis and Rheumotology Research, PLLC /ID# 160036

    Phoenix, Arizona

  • AZ Arthritis & Rheuma Research /ID# 160037

    Phoenix, Arizona

  • AZ Arth & Rheum Res /ID# 166381

    Tucson, Arizona

  • Little Rock Diagnostics Clinic /ID# 165161

    Little Rock, Arkansas

  • Covina Arthritis Clinic /ID# 159891

    Covina, California

  • St. Joseph Heritage Healthcare /ID# 159980

    Fullerton, California

  • C.V. Mehta MD, Med Corporation /ID# 161216

    Hemet, California

  • Care Access Research, Huntingt /ID# 160038

    Huntington Beach, California

  • Kotha and Kotha /ID# 159823

    La Mesa, California

  • TriWest Research Associates- La Mesa /ID# 159887

    La Mesa, California

  • Arthritis & Osteo Medical Ctr /ID# 166760

    La Palma, California

  • University of California, Los Angeles /ID# 164542

    Los Angeles, California

  • VA Sacramento Medical Center /ID# 164196

    Mather, California

  • East Bay Rheumatology Medical /ID# 166382

    San Leandro, California

  • Inland Rheum Clin Trials Inc. /ID# 159828

    Upland, California

  • Medvin Clinical Research /ID# 160034

    Whittier, California

  • Denver Arthritis Clinic /ID# 159873

    Denver, Colorado

  • Arthritis and Rheum Clin N. CO /ID# 160039

    Fort Collins, Colorado

  • Colorado Arthritis Associates /ID# 159847

    Lakewood, Colorado

  • Stamford Therapeutics Consorti /ID# 165131

    Stamford, Connecticut

  • Clinical Res of West FL, Inc. /ID# 159829

    Clearwater, Florida

  • International Medical Research - Daytona /ID# 160040

    Daytona Beach, Florida

  • Omega Research Maitland, LLC /ID# 164193

    DeBary, Florida

  • LeJenue Research Associates /ID# 170965

    Miami, Florida

  • Precision Research Org, LLC /ID# 161287

    Miami Lakes, Florida

  • Medallion Clinical Research Institute, LLC /ID# 161228

    Naples, Florida

  • Millennium Research /ID# 159822

    Ormond Beach, Florida

  • Arthritis Center, Inc. /ID# 163465

    Palm Harbor, Florida

  • Gulf Region Clinical Res Inst /ID# 159851

    Pensacola, Florida

  • BayCare Medical Group /ID# 159792

    St. Petersburg, Florida

  • W. Broward Rheum Assoc Inc. /ID# 161388

    Tamarac, Florida

  • Clinical Research of West Florida, Inc /ID# 160063

    Tampa, Florida

  • University of South Florida /ID# 161286

    Tampa, Florida

  • BayCare Medical Group, Inc. /ID# 159879

    Tampa, Florida

  • Florida Medical Clinic /ID# 159992

    Zephyrhills, Florida

  • Institute of Arthritis Researc /ID# 165873

    Idaho Falls, Idaho

Showing 40 of 345 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.